Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Harpole

Showing results (21-30 of 28) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 28 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 2, 2007
Pharmacogenomic strategies provide a rational approach to the treatment of cisplatin-resistant patients with advanced cancerDavid S Hsu, Bala S Balakumaran, Chaitanya R Acharya, et al.
Nature|November 8, 2005
Oncogenic pathway signatures in human cancers as a guide to targeted therapiesAndrea H Bild, Guang Yao, Jeffrey T Chang, et al.
Nature Medicine|October 24, 2006
Genomic signatures to guide the use of chemotherapeuticsAnil Potti, Holly K Dressman, Andrea Bild, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 28, 2017
Immune Activation in Early-Stage Non-Small Cell Lung Cancer Patients Receiving Neoadjuvant Chemotherapy Plus IpilimumabJohn S Yi, Neal Ready, Patrick Healy, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 2, 2019
Pathologic Considerations and Standardization in Mesothelioma Clinical TrialsMing-Sound Tsao, Michele Carbone, Francoise Galateau-Salle, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 22, 2025
Surgical Outcomes With Neoadjuvant Durvalumab Plus Chemotherapy Followed by Adjuvant Durvalumab in Resectable NSCLCTetsuya Mitsudomi, John V Heymach, Martin Reck, et al.
The New England Journal of Medicine|October 23, 2023
Perioperative Durvalumab for Resectable Non-Small-Cell Lung CancerJohn V Heymach, David Harpole, Tetsuya Mitsudomi, et al.
The Journal of Thoracic and Cardiovascular Surgery|October 12, 2024
Initial patient characteristics of Thoracic Surgical Oncology Group 102: A multicenter prospective registry of active surveillance in patients with multiple ground-glass opacitiesJames Huang, Kay See Tan, Nasser Altorki, et al.
Pageof 3

Showing results (21-30 of 28) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 28 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 2, 2007
Pharmacogenomic strategies provide a rational approach to the treatment of cisplatin-resistant patients with advanced cancerDavid S Hsu, Bala S Balakumaran, Chaitanya R Acharya, et al.
Nature|November 8, 2005
Oncogenic pathway signatures in human cancers as a guide to targeted therapiesAndrea H Bild, Guang Yao, Jeffrey T Chang, et al.
Nature Medicine|October 24, 2006
Genomic signatures to guide the use of chemotherapeuticsAnil Potti, Holly K Dressman, Andrea Bild, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 28, 2017
Immune Activation in Early-Stage Non-Small Cell Lung Cancer Patients Receiving Neoadjuvant Chemotherapy Plus IpilimumabJohn S Yi, Neal Ready, Patrick Healy, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 2, 2019
Pathologic Considerations and Standardization in Mesothelioma Clinical TrialsMing-Sound Tsao, Michele Carbone, Francoise Galateau-Salle, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 22, 2025
Surgical Outcomes With Neoadjuvant Durvalumab Plus Chemotherapy Followed by Adjuvant Durvalumab in Resectable NSCLCTetsuya Mitsudomi, John V Heymach, Martin Reck, et al.
The New England Journal of Medicine|October 23, 2023
Perioperative Durvalumab for Resectable Non-Small-Cell Lung CancerJohn V Heymach, David Harpole, Tetsuya Mitsudomi, et al.
The Journal of Thoracic and Cardiovascular Surgery|October 12, 2024
Initial patient characteristics of Thoracic Surgical Oncology Group 102: A multicenter prospective registry of active surveillance in patients with multiple ground-glass opacitiesJames Huang, Kay See Tan, Nasser Altorki, et al.
Pageof 3